AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

1.900

+0.22013.10%

Volume:3.54M

Turnover:6.54M

Market Cap:610.57M

PE:-11.73

High:1.960

Open:1.700

Low:1.675

Close:1.680

Loading ...

Overview Company News Filings

Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences

Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-Bispsma in Biochemical Recurrence of Prostate Cancer

THOMSON REUTERS

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

BUZZ-Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug

Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher

BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation For Cu- 64 Sar-Bispsma

Clarity jumps as FDA awards fast track status for PET scan imaging agent

The Market Herald

Guess which ASX 200 biotech stock is jumping 15% on big US FDA news

Clarity Pharmaceuticals Secures Fast Track Designation from US FDA for Prostate Cancer Imaging Agent; Shares Rise 4%

MT Newswires Live

Clarity Pharmaceuticals - U.S. FDA Fast Track Designation for Cu- 64 SAR-Bispsma in Biochemical Recurrence of Prostate Cancer

THOMSON REUTERS

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Simply Wall St.

This fund returned 109% in 2024. Here are 2 of its best-performing ASX shares

Best ASX 200 shares vs. best suburbs for property investment in 2024

Here's how the ASX 200 market sectors stacked up last week

3 ASX small-cap shares that ripped 295% to 900% in 2024

16 ASX shares that doubled in value last year

Shares vs. property: Which investment delivered the best capital growth in 2024?

Here are the top 10 ASX 200 shares today

Healthy gains: 5 best ASX 200 healthcare shares of 2024

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CU6.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":1.9,"timestamp":1744870320000,"preClose":1.68,"halted":0,"volume":3540508,"delay":0,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":225167378,"shares":321351612,"eps":-0.161928,"marketStatus":"Closed Easter Monday","change":0.22,"latestTime":"04-17 16:12:00 AEST","open":1.7,"high":1.96,"low":1.675,"amount":6540576,"amplitude":0.169643,"askPrice":1.92,"askSize":8366,"bidPrice":1.9,"bidSize":4997,"shortable":3,"etf":0,"ttmEps":-0.161928,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":1.68,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.3000482564866602,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":225167378,"roa":"-36.11%","roe":"-53.99%","lyrEps":-0.154944,"volumeRatio":1.3000482564866602,"shares":321351612,"dividePrice":0,"high":1.96,"amplitude":0.169643,"preClose":1.68,"low":1.675,"week52Low":1.43,"pbRate":"4.79","psRate":"56.66","week52High":8.975,"institutionHeld":0,"latestPrice":1.9,"committee":-0.252114,"eps":-0.161928,"divideRate":0,"volume":3540508,"delay":0,"ttmEps":-0.161928,"open":1.7,"prevYearClose":4.17,"prevWeekClose":1.9,"prevMonthClose":2.11,"prevQuarterClose":2.11,"fiveDayClose":1.655,"twentyDayClose":2.83,"sixtyDayClose":3.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506224519","title":"Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2506224519","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506224519?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:04","pubTimestamp":1738073040,"startTime":"0","endTime":"0","summary":"Two abstracts on Clarity's diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium  2025.An abstract on the COBRA study has also been selected for presentation at the American Urological Association  Annual Meeting 2025.In a subset of participants in the COBRA study who underwent follow-up SOC PSMA PET, 70% of participants had a positive scan on same-day imaging and 90% on next-day imaging using 64Cu-SAR-bisPSMA, compared to 60% of participants using SOC PSMA PET where only same-day imaging is possible. The number of lesions across all participants  identified by 64Cu-SAR-bisPSMA was also higher  than that detected by SOC PET agents . Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents. Across all participants in the study, histopathology confirmed the presence of prostate cancer in lesions iden","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4141","BK7061","BK4512","TGA.AU","ON","CU6.AU","BK7096","BK7001","BK4135","BK7003","IE00BZ199S13.USD","LU1720051108.HKD","LU1861214812.USD","SAR.AU","LU1861220033.SGD","LU0124384867.USD","PET.AU","BK4213","IE00BD6J9T35.USD","BCR","SAR","LU1854103824.USD","AUA.AU","TGA","LU1978683503.SGD","SOC.AU","BK4588","LU0724618433.USD","LU0348723411.USD","BK7047","LU1548497426.USD","BK4192","BK4585","LU2298322129.HKD","PET","LU1720051017.SGD","LU1854104046.USD","LU1861219969.SGD","LU2357305700.SGD","LU1861215975.USD","SOC","LU2360107325.USD"],"gpt_icon":0},{"id":"2505680078","title":"Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-Bispsma in Biochemical Recurrence of Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505680078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505680078?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:02","pubTimestamp":1737727324,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nTUA515NP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2505865344","title":"Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505865344","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505865344?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:02","pubTimestamp":1737727320,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of an FTD for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1]. These 2 FTDs enable the Company to accelerate the development of its comprehensive diagnostic program with this product.The FDA's FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For 64Cu-SAR-bisPSMA, it provides a number of product development advantages. The designation paves the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7061","CU6.AU","SAR.AU","BK4135","BK7001","IE00BYQQ9H92.USD","BK4588","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK4585","BK7047","BK4567","BK4192","PET.AU","SAR","TGA","TGA.AU","FAST","BK7096","SOC.AU","BK4104","BK4213","SOC","BCR","PET"],"gpt_icon":0},{"id":"2505070602","title":"BUZZ-Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505070602","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505070602?lang=en_us&edition=fundamental","pubTime":"2025-01-24 10:24","pubTimestamp":1737685444,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at A$4.135, set for a fourth consecutive session of gain** Radiopharma co says the U.S. Food and Drug Administration has granted Fast Track Designation for its prostate cancer drug, 64Cu-SAR-bisPSMA** Says the drug has several advantages over currently approved ones, including improved diagnostic performance and flexible imaging schedule, among others** Stock rises as much as 15.5% earlier in the day, marking its biggest intraday pct gain since Dec. 18, 2024 ** About 2 mln shares change hands, 1.1x the 30-avg** Stock more than doubled in value last year  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nL3N3OK06A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2505074824","title":"Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074824?lang=en_us&edition=fundamental","pubTime":"2025-01-24 09:29","pubTimestamp":1737682171,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index  is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,410.4 points.Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:. The Clarity Pharmaceuticals share price is up 3.5% to $4.20. This follows news that the U.S. Food and Drug Administration  has granted Fast Track Designation  for 64Cu-SAR-bisPSMA. This is for positron emission tomography  imaging of prostate-specific membrane antigen  positive prostate cancer lesions in patients with biochemical recurrence  of prostate cancer following definitive therapy. Clarity executive chair, Dr Alan Taylor, said: \"Receiving the second FTD for 64Cu-SAR-bisPSMA and well within the 60-day period following our application submission, reserved by the U.S. FDA for review, is yet another significant milestone in our bisPSMA program.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/why-clarity-genesis-energy-igo-and-wesfarmers-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PLS.AU","BK4504","LU1668664300.SGD","IGO.AU","BK7096","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2237438978.USD","LU2237443549.SGD","BK7078","BK4585","BK7504","BK4588","IE00BFXG1179.USD","BK7506","LU2237443978.SGD","IE0004091025.USD","LU2237443895.HKD","BK7047","IE0004086264.USD","BK4552","IE0034235188.USD","XJO.AU","BK7041","BK4533","LU0106831901.USD","LU2237443382.USD","PET.AU","LU2237443465.HKD","IE00B19Z3581.USD","LU2237443622.USD","IE0002270589.USD","BK7006","BK4127","BK4516","GNE.AU","BK7153","BK7511","BK4550","PET","BK4192","TLC.AU","WES.AU","BCR","LU1791807156.HKD","BK7507","CU6.AU","BK7095"],"gpt_icon":0},{"id":"2505207108","title":"BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation For Cu- 64 Sar-Bispsma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505207108","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505207108?lang=en_us&edition=fundamental","pubTime":"2025-01-24 09:28","pubTimestamp":1737682130,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation For Cu- 64 Sar-BispsmaJan 24  - Clarity Pharmaceuticals Ltd CU6.AX:U.S. FDA FAST TRACK DESIGNATION FOR CU- 64 SAR-BISPSMA IN BIOCHEMICAL RECURRENCE OF PROSTATE CANCERFurther company coverage: CU6.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OJ1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2505600298","title":"Clarity jumps as FDA awards fast track status for PET scan imaging agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2505600298","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505600298?lang=en_us&edition=fundamental","pubTime":"2025-01-24 08:47","pubTimestamp":1737679620,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer.The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen the company’s price climb to as much as $8/sh over the last six months.One-year returns are up 84%, but just a few months ago, were far higher. Source: TradingView. Clarity’s market cap currently sits above $1 billion, seeing it join a class of companies on the ASX in biotech undergoing something of a boom.While Clarity’s announcement it’s received fast-track status from the FDA for its copper-based Cu-64 SAR-bisPSMA imaging agent doesn’t reflect a full approval for use in the U.S., it does underscore regulator interest in the agent.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/clarity-jumps-as-fda-awards-fast-track-status-for-pet-scan-imaging-agent-2025-01-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PET","CU6.AU","BK7096","BK4192"],"gpt_icon":0},{"id":"2505107139","title":"Guess which ASX 200 biotech stock is jumping 15% on big US FDA news","url":"https://stock-news.laohu8.com/highlight/detail?id=2505107139","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505107139?lang=en_us&edition=fundamental","pubTime":"2025-01-24 07:58","pubTimestamp":1737676722,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd  shares are ending the week on a high. In early trade, the ASX 200 biotech stock was up as much as 15% to $4.69. Its shares have since pulled back but remain up 3% to $4.19 at the time of writing. Why is this ASX 200 biotech stock jumping?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/guess-which-asx-200-biotech-stock-is-jumping-15-on-big-us-fda-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4192","BCR","BK7047","BK7096","CU6.AU","PET.AU","PET"],"gpt_icon":0},{"id":"2505007800","title":"Clarity Pharmaceuticals Secures Fast Track Designation from US FDA for Prostate Cancer Imaging Agent; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505007800","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505007800?lang=en_us&edition=fundamental","pubTime":"2025-01-24 07:52","pubTimestamp":1737676378,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd  secured a fast-track designation from the US Food and Drug Administration for the prostate cancer imaging agent 64Cu-SAR-bisPSMA, according to a Friday filing with the Australian bourse.The designation will allow for an expedited regulatory review of the product, the filing said.Company shares rose past 4% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG0V08.USD","XAO.AU","BK4104","BK7096","XJO.AU","FAST","IE00B5TLWC47.USD","XKO.AU","BK4588","BK4567","CU6.AU","IE00BYQQ9H92.USD","BK4585"],"gpt_icon":0},{"id":"2505302223","title":"Clarity Pharmaceuticals - U.S. FDA Fast Track Designation for Cu- 64 SAR-Bispsma in Biochemical Recurrence of Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505302223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505302223?lang=en_us&edition=fundamental","pubTime":"2025-01-24 06:41","pubTimestamp":1737672079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nFWN3OJ1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2505596071","title":"We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2505596071","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505596071?lang=en_us&edition=fundamental","pubTime":"2025-01-24 04:28","pubTimestamp":1737664085,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/we-think-clarity-pharmaceuticals-asxcu6-can-easily-afford-to-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2505703664","title":"This fund returned 109% in 2024. Here are 2 of its best-performing ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2505703664","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505703664?lang=en_us&edition=fundamental","pubTime":"2025-01-23 04:00","pubTimestamp":1737576000,"startTime":"0","endTime":"0","summary":"When you're looking for the best ASX shares to add to your portfolio, sometimes it's helpful to let others do the heavy lifting. This is where investment funds come into play, and based on one fund ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/23/this-fund-returned-109-in-2024-here-are-2-of-its-best-performing-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7116","CU6.AU","IPX.AU"],"gpt_icon":0},{"id":"2503532068","title":"Best ASX 200 shares vs. best suburbs for property investment in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2503532068","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503532068?lang=en_us&edition=fundamental","pubTime":"2025-01-14 03:30","pubTimestamp":1736796600,"startTime":"0","endTime":"0","summary":"Were you invested in ASX 200 shares vs. property last year?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/14/best-asx-200-shares-vs-best-suburbs-for-property-investment-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","HUB.AU","BK7503","BK7096","CU6.AU","PNI.AU","XJO.AU","BK7067","PME.AU","360.AU","ZIP.AU","BK7054","XAO.AU","BK7016","CDA.AU","BK7093","BK7084","BK7094","TNE.AU","BK7062","BK7103","SIG.AU","XKO.AU"],"gpt_icon":0},{"id":"2502878743","title":"Here's how the ASX 200 market sectors stacked up last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2502878743","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502878743?lang=en_us&edition=fundamental","pubTime":"2025-01-12 05:00","pubTimestamp":1736629200,"startTime":"0","endTime":"0","summary":"ASX200 healthcareshares led themarket sectorswith a 1.15% increase over the five trading days. The S&P/ASX 200 Index(ASX: XJO) gained 0.53% over the week to finish at 8,294.1 points on Friday. Seven o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/12/heres-how-the-asx-200-market-sectors-stacked-up-last-week-22/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["COH.AU","TLX.AU","RHC.AU","CU6.AU","BK7007","BK7067","BK7511","MSB.AU","BK7113","CSL.AU","SIG.AU","RMD.AU","BK7096","BK7508","FPH.AU","BK7103","SHL.AU","BK7094","BK7124","PME.AU","BK7501","XJO.AU"],"gpt_icon":0},{"id":"2502883159","title":"3 ASX small-cap shares that ripped 295% to 900% in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2502883159","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502883159?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:08","pubTimestamp":1736482139,"startTime":"0","endTime":"0","summary":"ASX small-cap shares put in a solid performance last year, with the S&P/ASX Small Ordinaries Index (ASX: XSO) rising 5.54% and delivering total returns, including dividends, of 8.36%.  By comparison, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-small-cap-shares-that-ripped-295-to-900-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CDA.AU","BK7104","BK7501","IPX.AU","CU6.AU","BK7093","BK7067","XJO.AU","BK7084","XKO.AU","SPR.AU","BK7116","SLC.AU","BK7103","BK7096","MSB.AU","XAO.AU","PNI.AU","NXL.AU","360.AU","BK7015","BK7062","ZIP.AU","SIG.AU","BK7508","BK7016"],"gpt_icon":0},{"id":"2502088116","title":"16 ASX shares that doubled in value last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2502088116","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502088116?lang=en_us&edition=fundamental","pubTime":"2025-01-09 04:00","pubTimestamp":1736366400,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% last year and delivered total gross returns, including dividends, of 11.44%. The index closed the year at 8,420.5 points.  In comparison, t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/16-asx-shares-that-doubled-in-value-last-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7015","BK7501","BK7503","BK7104","APX.AU","SIG.AU","XAO.AU","CAT.AU","IPX.AU","LIF","TLX.AU","BK7016","CU6.AU","BK7508","OBM.AU","BK7116","BK7067","BK7096","BK7084","MSB.AU","BK7093","XJO.AU","BK7094","PME.AU","ZIP.AU","PNI.AU","SPR.AU","TNE.AU","360.AU","NXL.AU","BK7062","BK7103","BK4023","SLC.AU","BK7061"],"gpt_icon":0},{"id":"2502776702","title":"Shares vs. property: Which investment delivered the best capital growth in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502776702","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502776702?lang=en_us&edition=fundamental","pubTime":"2025-01-09 03:00","pubTimestamp":1736362800,"startTime":"0","endTime":"0","summary":"Let's look back and see which ASX shares vs. property markets delivered the best capital gains in 2024.  Shall we start with stocks?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/shares-vs-property-which-investment-delivered-the-best-capital-growth-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7067","BK7084","BK7103","BK7054","BK7062","SIG.AU","CDA.AU","BK7094","PNI.AU","PME.AU","360.AU","XKO.AU","HUB.AU","TLX.AU","XAO.AU","BK7096","CU6.AU","BK7093","TNE.AU","XJO.AU","BK7016","ZIP.AU"],"gpt_icon":0},{"id":"2501426952","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2501426952","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501426952?lang=en_us&edition=fundamental","pubTime":"2025-01-07 14:03","pubTimestamp":1736229792,"startTime":"0","endTime":"0","summary":"Welcome to our first top ten list for 2025!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/here-are-the-top-10-asx-200-shares-today-558/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7052","CU6.AU","BK7503","AD8.AU","QAN.AU","BK7132","BK7054","IEL.AU","CAR.AU","BK7135","BK7096","BK7086","BK7016","BK7073","SDR.AU","HUB.AU","BAP.AU","BK7030","JDO.AU","BK7002","XJO.AU","NEC.AU"],"gpt_icon":0},{"id":"2501666962","title":"Healthy gains: 5 best ASX 200 healthcare shares of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2501666962","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501666962?lang=en_us&edition=fundamental","pubTime":"2025-01-07 02:00","pubTimestamp":1736186400,"startTime":"0","endTime":"0","summary":"ASX 200 healthcareshares performed well in 2024, with theS&P/ASX 200 Health Care Index(ASX: XHJ) rising 6.01% and delivering a 12-month total return, including dividends, of 7.51%. However, the health","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/healthy-gains-5-best-asx-200-healthcare-shares-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","BK7067","SIG.AU","PME.AU","CU6.AU","BK7096","BK7501","TLX.AU","BK7007","FPH.AU","XJO.AU","BK7103"],"gpt_icon":0},{"id":"2492189536","title":"Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2492189536","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492189536?lang=en_us&edition=fundamental","pubTime":"2024-12-18 22:03","pubTimestamp":1734530580,"startTime":"0","endTime":"0","summary":"The product, termed SAR-bisFAP, has shown strong tumour targeting, retention and pharmacokinetic data to date in pre-clinical models.FAP is expressed widely across a range of malignancies, opening a very large pan-cancer opportunity for both imaging and treatment of various cancers.Clarity continues to develop a range of novel products through its Discovery Program with strong patent protection aimed at improving treatment outcomes in indications with high unmet needs.FAP is expressed on cancer associated fibroblasts , a particular cell type found in the tumour microenvironment . CAFs are found in a broad range of cancers , but only minimally in normal tissue, making FAP a promising pan-cancer target for both imaging and treatment of cancers1. CAFs form part of the environment surrounding the cancer cells, and they can promote cancer growth and the spread of the tumour throughout the body2. Targeting the tumour stroma is an alternative way to treat cancer whereby the architecture of th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9fp57r7drKSqvSvMhd0Xgw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9fp57r7drKSqvSvMhd0Xgw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-expands-pipeline-novel-optimised-140300523.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-expands-pipeline-novel-optimised-140300523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","TGA.AU","BK7001","BK4213","TGA","CU6.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[]}}